BAB Reports GAAP EPS $0.02 on $0.73M Revenue: BAB posted GAAP EPS $0.02 and revenue $0.73M for the quarter (Seeking Alpha, Apr 10, 2026); liquidity and recurring revenue durability are the critical near-term… 👈 Read full analysis #EarningsReport #GAAPEPS #Revenue #FinancialResults #Investing
BAB Reports GAAP EPS $0.02 on $0.73M Revenue
BAB posted GAAP EPS $0.02 and revenue $0.73M for the quarter (Seeking Alpha, Apr 10, 2026); liquidity and recurring revenue durability are the critical near-term questions.
dlvr.it
April 10, 2026 at 8:45 AM
BAB Reports GAAP EPS $0.02 on $0.73M Revenue: BAB posted GAAP EPS $0.02 and revenue $0.73M for the quarter (Seeking Alpha, Apr 10, 2026); liquidity and recurring revenue durability are the critical near-term… 👈 Read full analysis #EarningsReport #GAAPEPS #Revenue #FinancialResults #Investing
Pardee Resources Q1 GAAP EPS $25.09: Pardee Resources reported GAAP EPS of $25.09 and revenue of $46.88M on Apr 6, 2026; the outsized EPS likely reflects non-recurring items and requires cash-flow… 👈 Read full analysis #PardeeResources #GAAPEPS #FinancialReporting #EarningsRelease #Investing
Pardee Resources Q1 GAAP EPS $25.09
Pardee Resources reported GAAP EPS of $25.09 and revenue of $46.88M on Apr 6, 2026; the outsized EPS likely reflects non-recurring items and requires cash-flow scrutiny.
dlvr.it
April 6, 2026 at 8:52 AM
Pardee Resources Q1 GAAP EPS $25.09: Pardee Resources reported GAAP EPS of $25.09 and revenue of $46.88M on Apr 6, 2026; the outsized EPS likely reflects non-recurring items and requires cash-flow… 👈 Read full analysis #PardeeResources #GAAPEPS #FinancialReporting #EarningsRelease #Investing
MicroAlgo Reports GAAP EPS $2.12, Revenue $60.05M: MicroAlgo reported GAAP EPS $2.12 and revenue $60.05M on Apr 2, 2026; investors should probe revenue mix, client concentration, and deferred revenue to assess… 👈 Read full analysis #MicroAlgo #EarningsReport #GAAPEPS #RevenueGrowth #Investing
MicroAlgo Reports GAAP EPS $2.12, Revenue $60.05M
MicroAlgo reported GAAP EPS $2.12 and revenue $60.05M on Apr 2, 2026; investors should probe revenue mix, client concentration, and deferred revenue to assess earnings quality.
dlvr.it
April 2, 2026 at 7:10 AM
MicroAlgo Reports GAAP EPS $2.12, Revenue $60.05M: MicroAlgo reported GAAP EPS $2.12 and revenue $60.05M on Apr 2, 2026; investors should probe revenue mix, client concentration, and deferred revenue to assess… 👈 Read full analysis #MicroAlgo #EarningsReport #GAAPEPS #RevenueGrowth #Investing
iFabric Corp Q1 GAAP EPS -$0.01: iFabric reported GAAP EPS of -$0.01 on Mar 31, 2026 (Seeking Alpha); the one-cent loss requires follow-up on cash flow and accounting drivers. 👈 Read full analysis #iFabric #GAAPEPS #EarningsReport #FinancialResults #SmallCapStocks
iFabric Corp Q1 GAAP EPS -$0.01
iFabric reported GAAP EPS of -$0.01 on Mar 31, 2026 (Seeking Alpha); the one-cent loss requires follow-up on cash flow and accounting drivers.
dlvr.it
March 31, 2026 at 2:14 PM
iFabric Corp Q1 GAAP EPS -$0.01: iFabric reported GAAP EPS of -$0.01 on Mar 31, 2026 (Seeking Alpha); the one-cent loss requires follow-up on cash flow and accounting drivers. 👈 Read full analysis #iFabric #GAAPEPS #EarningsReport #FinancialResults #SmallCapStocks
RenovoRx Reports Q1 GAAP EPS -$0.32, Revenue $1.12M: RenovoRx reported GAAP EPS -$0.32 and revenue $1.12M for Q1 2026, missing consensus by $0.18M (≈13.8%) on Mar 30, 2026 (Seeking Alpha). 👈 Read full analysis #RenovoRx #EarningsReport #GAAPEPS #FinanceNews #InvestmentInsights
RenovoRx Reports Q1 GAAP EPS -$0.32, Revenue $1.12M
RenovoRx reported GAAP EPS -$0.32 and revenue $1.12M for Q1 2026, missing consensus by $0.18M (≈13.8%) on Mar 30, 2026 (Seeking Alpha).
dlvr.it
March 30, 2026 at 9:05 PM
RenovoRx Reports Q1 GAAP EPS -$0.32, Revenue $1.12M: RenovoRx reported GAAP EPS -$0.32 and revenue $1.12M for Q1 2026, missing consensus by $0.18M (≈13.8%) on Mar 30, 2026 (Seeking Alpha). 👈 Read full analysis #RenovoRx #EarningsReport #GAAPEPS #FinanceNews #InvestmentInsights
Electra Battery Materials Posts GAAP EPS of -C$4.16: Electra reported GAAP EPS of -C$4.16 on Mar 30, 2026 (Source: Seeking Alpha). This large loss heightens liquidity and execution scrutiny… 👈 Read full analysis #ElectraBatteryMaterials #GAAPEPS #BatteryMaterials #MarketInsights #FinancialAnalysis
Electra Battery Materials Posts GAAP EPS of -C$4.16
Electra reported GAAP EPS of -C$4.16 on Mar 30, 2026 (Source: Seeking Alpha). This large loss heightens liquidity and execution scrutiny amid volatile battery-material prices (~60–70% down from 2022 peaks, BMI 2024).
dlvr.it
March 30, 2026 at 9:24 AM
Electra Battery Materials Posts GAAP EPS of -C$4.16: Electra reported GAAP EPS of -C$4.16 on Mar 30, 2026 (Source: Seeking Alpha). This large loss heightens liquidity and execution scrutiny… 👈 Read full analysis #ElectraBatteryMaterials #GAAPEPS #BatteryMaterials #MarketInsights #FinancialAnalysis
Athira Pharma Posts GAAP EPS of -$24.70: Athira Pharma reported GAAP EPS of -$24.70 on Mar 27, 2026; investors should await the 10-Q to parse non-cash items, cash runway and financing needs. 👈 Read full analysis #AthiraPharma #GAAPEPS #Investing #FinanceNews #StockMarket
Athira Pharma Posts GAAP EPS of -$24.70
Athira Pharma reported GAAP EPS of -$24.70 on Mar 27, 2026; investors should await the 10-Q to parse non-cash items, cash runway and financing needs.
dlvr.it
March 27, 2026 at 9:51 AM
Athira Pharma Posts GAAP EPS of -$24.70: Athira Pharma reported GAAP EPS of -$24.70 on Mar 27, 2026; investors should await the 10-Q to parse non-cash items, cash runway and financing needs. 👈 Read full analysis #AthiraPharma #GAAPEPS #Investing #FinanceNews #StockMarket
Medicus Pharma Reports GAAP EPS $2.74: Medicus Pharma reported GAAP EPS of $2.74 on Mar 26, 2026 (Seeking Alpha); investors should await the 8-K/10-Q for reconciliations and details on recurring revenue. 👈 Read full analysis #MedicusPharma #GAAPEPS #Investing #FinanceNews #StockMarket
Medicus Pharma Reports GAAP EPS $2.74
Medicus Pharma reported GAAP EPS of $2.74 on Mar 26, 2026 (Seeking Alpha); investors should await the 8-K/10-Q for reconciliations and details on recurring revenue.
dlvr.it
March 26, 2026 at 10:00 AM
Medicus Pharma Reports GAAP EPS $2.74: Medicus Pharma reported GAAP EPS of $2.74 on Mar 26, 2026 (Seeking Alpha); investors should await the 8-K/10-Q for reconciliations and details on recurring revenue. 👈 Read full analysis #MedicusPharma #GAAPEPS #Investing #FinanceNews #StockMarket
Innate Pharma Posts GAAP EPS -€0.55, Revenue €9.01M: Innate Pharma reported GAAP EPS of -€0.55 and revenue €9.01M on Mar 26, 2026 (Seeking Alpha). Immediate focus: cash runway, milestone timing, and… 👈 Read full analysis #InnatePharma #GAAPEPS #RevenueReport #ClinicalTrials #FinancialAnalysis
Innate Pharma Posts GAAP EPS -€0.55, Revenue €9.01M
Innate Pharma reported GAAP EPS of -€0.55 and revenue €9.01M on Mar 26, 2026 (Seeking Alpha). Immediate focus: cash runway, milestone timing, and clinical catalysts.
dlvr.it
March 26, 2026 at 8:11 AM
Innate Pharma Posts GAAP EPS -€0.55, Revenue €9.01M: Innate Pharma reported GAAP EPS of -€0.55 and revenue €9.01M on Mar 26, 2026 (Seeking Alpha). Immediate focus: cash runway, milestone timing, and… 👈 Read full analysis #InnatePharma #GAAPEPS #RevenueReport #ClinicalTrials #FinancialAnalysis
Cheer Holding Reports GAAP EPS $24.07, Revenue $148.8M: Cheer Holding posted GAAP EPS $24.07 and $148.8M revenue on Mar 23, 2026, prompting immediate scrutiny of whether earnings are recurring or driven by… 👈 Read full analysis #CheerHolding #GAAPEPS #EarningsReport #RevenueGrowth #FinancialAnalysis
Cheer Holding Reports GAAP EPS $24.07, Revenue $148.8M
Cheer Holding posted GAAP EPS $24.07 and $148.8M revenue on Mar 23, 2026, prompting immediate scrutiny of whether earnings are recurring or driven by one-offs.
dlvr.it
March 23, 2026 at 8:19 PM
Cheer Holding Reports GAAP EPS $24.07, Revenue $148.8M: Cheer Holding posted GAAP EPS $24.07 and $148.8M revenue on Mar 23, 2026, prompting immediate scrutiny of whether earnings are recurring or driven by… 👈 Read full analysis #CheerHolding #GAAPEPS #EarningsReport #RevenueGrowth #FinancialAnalysis
Avalo Therapeutics Q4 GAAP EPS -$5.84 Beats Estimates: Avalo posted GAAP EPS of -$5.84 (beat by $0.47) and revenue $0.06M on Mar 23, 2026; cash runway and upcoming readouts remain decisive for… 👈 Read full analysis #AvaloTherapeutics #EarningsReport #GAAPEPS #FinancialResults #InvestmentInsights
Avalo Therapeutics Q4 GAAP EPS -$5.84 Beats Estimates
Avalo posted GAAP EPS of -$5.84 (beat by $0.47) and revenue $0.06M on Mar 23, 2026; cash runway and upcoming readouts remain decisive for valuation.
dlvr.it
March 23, 2026 at 11:46 AM
Avalo Therapeutics Q4 GAAP EPS -$5.84 Beats Estimates: Avalo posted GAAP EPS of -$5.84 (beat by $0.47) and revenue $0.06M on Mar 23, 2026; cash runway and upcoming readouts remain decisive for… 👈 Read full analysis #AvaloTherapeutics #EarningsReport #GAAPEPS #FinancialResults #InvestmentInsights
Vertex Resource Posts C$54.83M Revenue, GAAP EPS -C$0.06: Vertex Resource reported C$54.83M revenue and GAAP EPS of -C$0.06 on Mar 23, 2026; follow‑up on adjusted EBITDA, cash flow and backlog is essential. 👈 Read full analysis #VertexResource #EarningsReport #Revenue #GAAPEPS #FinancialNews
Vertex Resource Posts C$54.83M Revenue, GAAP EPS -C$0.06
Vertex Resource reported C$54.83M revenue and GAAP EPS of -C$0.06 on Mar 23, 2026; follow‑up on adjusted EBITDA, cash flow and backlog is essential.
dlvr.it
March 23, 2026 at 8:37 AM
Vertex Resource Posts C$54.83M Revenue, GAAP EPS -C$0.06: Vertex Resource reported C$54.83M revenue and GAAP EPS of -C$0.06 on Mar 23, 2026; follow‑up on adjusted EBITDA, cash flow and backlog is essential. 👈 Read full analysis #VertexResource #EarningsReport #Revenue #GAAPEPS #FinancialNews